1. Home
  2. MMS vs ARQT Comparison

MMS vs ARQT Comparison

Compare MMS & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Maximus Inc.

MMS

Maximus Inc.

N/A

Current Price

$53.98

Market Cap

3.2B

ML Signal

N/A

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

N/A

Current Price

$25.46

Market Cap

3.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MMS
ARQT
Founded
1975
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.2B
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
MMS
ARQT
Price
$53.98
$25.46
Analyst Decision
Buy
Buy
Analyst Count
2
7
Target Price
★ $92.50
$37.00
AVG Volume (30 Days)
548.7K
★ 2.4M
Earning Date
11-19-2026
10-27-2026
Dividend Yield
★ 2.48%
N/A
EPS Growth
10.42
★ 88.79
EPS
★ 5.45
0.03
Revenue
★ $2,392,236,000.00
$376,072,000.00
Revenue This Year
N/A
$42.88
Revenue Next Year
$2.89
$27.84
P/E Ratio
★ $9.78
$899.67
Revenue Growth
N/A
★ 91.34
52 Week Low
$51.04
$19.30
52 Week High
$100.00
$31.77

Technical Indicators

Market Signals
Indicator
MMS
ARQT
Relative Strength Index (RSI) 47.70 53.37
Support Level $53.19 $24.91
Resistance Level $60.42 $28.20
Average True Range (ATR) 1.55 1.44
MACD -0.17 0.16
Stochastic Oscillator 47.22 62.81

Price Performance

Historical Comparison
MMS
ARQT

About MMS Maximus Inc.

Maximus Inc designs, develops, and delivers programs enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments: U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment, which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Share on Social Networks: